Munoz-Pinto et al., 2021)
Ozempic did so well with treating type two diabetes, and also in the process they found that Ozempic was causing people to lose weight that Novo Nordisk said, well, lets re-market this, get this re-approved specifically for the indication of obesity
In 2009, modified fasting therapy was initially applied as a therapeutic option for the management of overweight, obesity and MetS in South China [3]
Kumawat M, Sharma TK, Singh I, Singh N, Ghalaut VS, Vardey SK, et al
Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose Co-Transporter-2 inhibition use in type 2 diabetes: Exploratory analysis of the AMPLITUDE-O trial
The worst thing you could possibly do is not realize when you're hungry